Zu den Inhalten springen

Hauptnavigation:

Kontakt | English | Sitemap

| Home > Zentren > Ambulanzzentrum > Publikationen

Neurologie

Publikationen

ResearchGate

 

Erst- und Letztautorenschaften:

Buhmann C (2010): Anwendung von transdermalem Rotigotin bei Patienten mit Morbus Parkinson und gastrointestinaler Resorptionsstörung - Fallbericht. In: Transdermales Rotigotin bei M. Parkinson und Restless-Legs Syndrom, Redecker C (Hrsg), Thieme: 12-14

Buhmann C, Roscher T. Stalevo® zur Nacht bei Parkinson-Patienten (2010). Thieme Praxis Report 2010; 1: 1-18

Buhmann C, Klucken J, Korchounov A, Schwarz M, Vieregge P, Jost W (2010): Wann sollten wir mit der medikamentösen Therapie beim M. Parkinson beginnen? (When should we start medical treatment in Parkinson disease?) Fortschr Neurol Psychiatr, 78 (Suppl 1): 31-3

Buhmann C (2009): Therapie geriatrischer Patienten mit M. Parkinson. Akt Neurol, 36 (Suppl. 4): 312-319 

Buhmann C (2009): Morbus Parkinson. Können wir die Erkrankung aufhalten? Info Neurologie & Psychiatrie, 11 (10): 2-7  

Buhmann C (2009): State of the Art - M. Parkinson. PharmaFokus ZNS, 6. Jahrg.: 24-27

Buhmann C (2008): Diagnostik und Therapie des M. Parkinson beim älteren Patienten. Neurogeriatrie, NeuroGeriatrie, 5 (4): 135-143

Buhmann C (2007): Klinik, Differentialdiagnostik und Therapie des M. Parkinson. focus neurogeriatrie, 4/2007, 2-8 

Buhmann C (2007): Lewy-Körper-Demenz (LBD). Neue Diagnosemöglichkeit verbessert Patientenmanagement. Neuro-Psychiatrische Nachrichten, 03-04/2007 

Buhmann C, Pramstaller PP, Binkofski F, Erdmann C, Hedrich K, Hagenah J, van Eimeren T, Büchel C, Deuschl G, Klein C, Siebner HR (2005): Motor cortex reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain, 128: 2281-90

Buhmann C, Gorsler A, Bäumer T, Hidding U, Demiralay C, Hinkelmann K, Weiller C, Siebner HR, Münchau A (2004): Abnormal excitability of premotor-motor connections in de novo Parkinson's disease. Brain,127: 2732-46

Buhmann C, Arlt S, Kontush A, Möller-Bertram T, Sperber S, Oechsner M, Stürenburg HJ, Beisiegel U (2004): CSF and plasma lipoprotein oxidation is increased in Parkinson´s disease independently of levodopa treatment. Neurobiol Dis,15:160 -70

Buhmann C, Stürenburg HJ, Oechsner M, Glauche V, Weiller C, Büchel C (2003): Pharmacologically modulated fMRI - Cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. Brain, 126: 451-61

Buhmann C, Bussopulos A, Oechsner M (2002): Dopaminergic response with best effect for pramipexole in parkinsonian phenotype of Machado-Joseph Disease. Mov Disord,18:219-21 (3.093)

Buhmann C, Gbadamosi J, Heesen C (2002): Visual recovery in a man with the rare combination of mtDNA 11778 LHON mutation and a MS-like disease after mitoxantrone therapy. Acta Neurol Scand, 106: 236-239 

Buhmann C, Kretschmann HJ (1998): Computer-assisted three-dimensional reconstruction of the corticospinal system as a reference for CT and MRI. Neuroradiology, 40 (9): 549-557 (1.515)

Heesen C, Bruegmann M, Gbdamosi J, Koch E, Mönch A, Buhmann C (2003): Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler, 9(2): 213-4

Co-Autorenschaften:

Kertelge L, Brüggemann N, Schmidt A, Tadic V, Wisse C, Dankert S, Drude L, van der Vegt J, Siebner H, Pawlack H, Pramstaller PP, Behrens MI, Ramirez A, Reichel D, Buhmann C, Hagenah J, Klein C, Lohmann K, Kasten M (2010): Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson disease. Mov Disord. 25(15):2665-9

Kasten M, Kertelge L, Brüggemann N, van der Vegt J, Schmidt A, Tadic V, Buhmann C, Steinlechner S, Behrens MI, Ramirez A, Binkofski F, Siebner H, Raspe H, Hagenah J, Lencer R, Klein C (2010): Nonmotor symptoms in genetic Parkinson disease. Arch Neurol. Jun;67(6):670-6

Derlin T, Afzal W, Wilke F, Apostolova I, Klutmann S, Meyer PT, Buhmann C, Hesse S, Buchert R. (2010): IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes. Comparison with respect to interrater agreement. Nuklearmedizin, 49(4):139-47

van Eimeren T, Binkofski F, Buhmann C, Hagenah J, Strafella AP, Pramstaller PP, Siebner HR, Klein C. (2010): Imaging movement-related activity in medicated Parkin-associated and sporadic Parkinson's disease. Parkinsonism Relat Disord. 2010 Jul;16(6):384-387

van Nuenen B, van Eimeren T, van der Vegt J, Buhmann C, Klein C, Bloem B, Siebner H (2009): Mapping preclinical compensation in Parkinson's disease: an imaging genomics approach. Mov Disord., 24 (Suppl 2):703-10

Moll CKE, Sharott A, Hamel W, Münchau A, Buhmann C, Hidding U, Zittel S, Westphal M, Müller D, Engel AK (2009): Waking up the brain. A case study of stimulation-induced wakeful unawareness during anaesthesia. Coma Science: Clinical and Ethical Implications, Prog Brain Res. ,177:125-45

Tadic V, Kertelge L, Brüggemann N, Schmidt A, Wisse C, Drude L. Vegt van der J, Schneider SA, Siebner HR, Lohmann K, Buhmann C, Hagenah J, Klein C, Kasten M (2009): Beeinträchtigung der Geruchs- und Farbwahrnehmung bei genetischen und nicht genetischen Parkinson-syndromen. Akt Neurol, S2: 202

Zittel S, Mol CKE, Hamel W, Buhmann C, Engel AK, Gerloff C, Münchau A  (2009): Successful GPi deep brain stimulation in a patient with adult onset primary axial dystonia. JNNP, 80: 811-812

Eimeren van T, Buhmann C, Hagenah J, Pramstaller PP, Siebner H, Klein C (2009): Equally normalized motor activation in medicated Parkin-associated and sporadic PD. Mov Disord., 24 (Suppl.1): 217

Bäumer T, Hidding U, Hamel W, Buhmann C, Moll CK, Gerloff C, Orth M, Siebner HR, Münchau A. (2009): Effects of DBS, premotor rTMS, and levodopa on motor function and silent period in advanced Parkinson's disease. Mov Disord., 24(5):672-6

Jost W,  Buhmann C,  Fuchs G, Greulich W, Hummel S, Korchounov A,  Müngersdorf M, Schwarz M, Spiegel-Meixensberger M (2008): Initial experience with ropinirole PR (prolonged release). J Neurol, 255 [Suppl 5]:60-63

Wüllner U, Buhmann C, Hilker R, Hummel S, Korchounov A, Müller T, Paulus W, Schwartz A (2007): Therapie der Zukunft -Future Therapeutic Options in Parkinson's Disease. Akt Neurol, 34: 18-20

Moll CKE, Sharott A., Buhmann C, Hidding U, Zittel S, Westphal M et al. (2007). Intraoperative arousal reaction due to electrical stimulation of the globus pallidus. Acta Physiologica, 189: P20-L1-01

Hidding U, Bäumer T, Demiralay C, Siebner HR, Buhmann C, Hamel W, Münchau A (2006): MEP latency shift after implantation of deep brain stimulation systems in the subthalamic nucleus in patients with advanced Parkinson's disease. Mov Disord, 21(9):1471-6

Weiller C, May A, Sach M, Buhmann C, Rijntjes M (2006): Role of functional imaging in neurological disorders. J Magn Reson Imaging, 23(6): 840-50

Strekalova H, Buhmann C, Kleene R, Eggers C, Saffell J, Hemperly J, Weiller C, Müller-Thomsen T, Schachner M (2006). Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. Neurobiol Aging, 27: 1-9

Dong-Si T, Weber J, Liu Y, Buhmann C,  Bauer H, Bendl C, Schnitzler P, Grond-Ginsbach C, Grau A (2004): Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. J Neurol, 251: 542-547

Stürenburg HJ, Petersen K, Buhmann C, Rosenkranz M, Bäumer T, Thomasius R (2003): Plasma amino acids in ecstasy users. Neuroendocrinol Lett, 24: 348-9

Ganzer S, Arlt S, Schoder V, Buhmann C, Mandelkow EM, Finckh U, Beisiegel U, Naber D, Muller-Thomsen T (2003): CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity. J Neural Transm, 110: 1149-60

Gbadamosi J, Buhmann C, Tessmer W, Mönch A, Haag F, Heesen C (2003): Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF alpha, and IL-10. Eur Neurol, 49: 137-41

Arlt S, Kontush A, Zerr I, Buhmann C, Jacobi C, Schroeter A, Poser S, Beisiegel U (2002): Increased lipid peroxidation in cerebrospinal fluid and plasma from patients with Creutzfeldt-Jakob disease. Neurobiol Dis, 10: 150-156

Stürenburg HJ, Petersen K, Bäumer T, Rosenkranz M, Buhmann C, Thomasius R (2002): Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users. Neuroendocrinol Lett, 23: 259-61 (1.048) 

Oechsner M, Buhmann C, Strauss J, Stürenburg HJ (2002): COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. J Neural Transm, 109: 69-75

Gbadamosi J, Buhmann C, Mönch A, Heesen C (2001): Failure of ondansetron in treating cerebellar tremor in MS patients - an open-label pilot study. Acta Neurol Scand, 104: 308-11

Heesen C, Gbadamosi J, Mingers D, Mönch A, Buhmann C (2001): Erfahrungen mit Mitoxantron. Hamburger Ärzteblatt, 9: 430-432 

Koch S, Donarski N, Goetze K, Kreckel M, Stürenburg HJ, Buhmann C, Beisiegel U (2001): Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res, 42(7): 1143-51

Gold SM, Heesen C, Schulz H, Guder U, Mönch A, Gbadamosi J, Buhmann C, Schulz KH (2001): Disease specific quality of life instruments in multiple sclerosis: Validation of the Hamburg Quality of Life Questionaire in Multiple Sclerosis (HAQUAMS). Mult Scler, 7: 119-130

Riederer P, Brücke T, Buhmann C, Müller T, Schwartz A, Storch A, Winner B (2000): Workshop II: "Neuroprotection" - the Lugano consensus. J Neurol, 247 (16): IV36-IV37: Erratum in J Neurol 2000, 248: 155

Heesen C, Gbadamosi J, Buhmann C, Pöhlau D, Hansen HC (2000): Bilaterale Ptose bei Multipler Sklerose - Fallbericht und Literaturübersicht. Akt Neurol, 27: 178-181 

Schippling S, Kontush A, Arlt S, Buhmann C, Stürenburg HJ, Mann U, Müller-Thomsen T, Beisiegel U (2000): Increased Lipoprotein Oxidation in Alzheimer´s Disease. Free Radic Biol Med, 28: 351-360

Heesen C, Sieverding F, Buhmann C, Gbadamosi J (2000): IL-1ra serum levels in disease stages of MS--a marker for progression? Acta Neurol Scand, 101(2): 95-97 

Schippling S, Kontush A, Arlt S, Daher D, Buhmann C, Stürenburg HJ, Mann U, Müller-Thomsen T, Beisiegel U (1999): Lipoprotein oxidation and Alzheimer's disease. In: Alzheimer's Disease and Related Disorders (Hrsg. Igbal K, Swaab, DF, Winblad B, Wisniewski, HM), John Wiley & Sons Ltd, 471-477

Heesen C, Hauer S, Hadji-Abdolrahim B, Berenbeck C, Buhmann C, Emskötter T (1999): Current status of multiple sclerosis therapy in Germany: a national survey. Eur J Neurol, 6: 35-38

Kretschmann HJ, Vogt H, Schütz T, Gerke M, Riedel A, Buhmann C, Wesemann M, Müller D (1991): Dreidimensionale Rekonstruktionen in der Neuroanatomie. Radiologe, 31: 481-488

Seitenanfang    Seite drucken


© Universitätsklinikum Hamburg-Eppendorf, Impressum
Letzte Änderung: Jennifer Kämpfert, 02.04.2012

Untersuchungsanmeldung

Telefonische Anmeldung unter

040 - 7410 - 52771

Anmeldung per Fax

040 - 7410 - 46783

Patienteninformation

Anhand dieses Fragebogens: "Tiefe Hinrstimulation", können sie überprüfen, ob Sie prinzipiell ein geeigneter Patient für die tiefe Hirnstimulation sind.